The Squalene Monooxygenase pipeline drugs market research report outlays comprehensive information on the Squalene Monooxygenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Squalene Monooxygenase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease which include the indications Onychomycosis (Tinea Unguium), and Tinea Pedis (Athlete Foot). It also reviews key players involved in Squalene Monooxygenase targeted therapeutics development with respective active and dormant or discontinued products.
The Squalene Monooxygenase pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Preclinical stages are 1, 2, and 2 respectively.
Squalene Monooxygenase overview
Squalene monooxygenase is an enzyme involved in the cholesterol biosynthesis pathway, specifically the conversion of squalene to 2,3-oxidosqualene and is considered to be a rate-limiting enzyme in steroid biosynthesis. This enzyme plays a crucial role in regulating cholesterol levels in the body.
For a complete picture of Squalene Monooxygenase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
